PRISMA-COSMIN for OMIs
A reporting guideline (PRISMA extension) specifying what must be reported in systematic reviews of outcome measurement instruments, including patient-reported outcome measures, across 54 sub-items.
What it is
— PRISMA-COSMIN for Outcome Measurement Instruments (OMIs) 2024 is a reporting guideline: a 34-item / 54-sub-item checklist that prescribes the minimum content a systematic review of measurement instruments must report. It is a content-specialized extension of the PRISMA 2020 statement, jointly developed and maintained by the COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) initiative and registered with the EQUATOR Network. "OMIs" includes patient-reported outcome measures (PROMs), clinician-reported, observer-reported, and performance-based outcome measures. The checklist organizes items around the parts of an OMI review that have no analogue in a treatment-effect review: which construct and target population the instrument measures, which measurement properties (content validity, structural validity, internal consistency, reliability, measurement error, construct validity, cross-cultural validity, responsiveness) were synthesized, how the quality of each property's evidence was rated, and how a recommendation for use was derived. It is a reporting standard only — it tells you what to write down, not how to judge an instrument.
When to use
— Use PRISMA-COSMIN when the unit of synthesis is an instrument, not a treatment effect: a systematic review whose question is "which OMI best measures construct X in population Y, and is the evidence for its measurement properties adequate?" This is the standard for the reporting section of any OMI/PROM systematic review submitted to a peer-reviewed journal, and for the instrument-selection evidence package that supports an HTA dossier, a core-outcome-set justification, or a regulatory fit-for-purpose argument (FDA PRO Guidance, EMA reflection papers) for a PRO endpoint. Decision rule for picking the right guideline: if you are reviewing measurement instruments, use PRISMA-COSMIN; if you are reviewing clinical or treatment effects, use base PRISMA 2020 (or PRISMA-DTA for diagnostic accuracy); if you are conducting the OMI review's methodology and risk-of-bias assessment, that is the COSMIN methodology (Prinsen 2018) and the COSMIN Risk of Bias checklist (Mokkink 2017), which PRISMA-COSMIN reports on but does not replace; if you are designing or reporting a single primary PROM validation study, use the COSMIN study-design checklist, not this reporting guideline.
What it requires
— The checklist enforces, among its domains: (1) an explicit eligibility frame defining the construct, population, instrument type, and the measurement properties of interest; (2) transparent, reproducible search strategy across databases plus instrument-specific filters; (3) a study-selection and data-extraction process keyed to measurement properties rather than effect estimates; (4) reporting of the content validity assessment (often the most consequential and least reported property); (5) reporting of the COSMIN Risk of Bias rating per property per study; (6) the evidence-synthesis method per property and the GRADE-style rating of the quality of evidence; (7) the derivation of the categorized recommendation (A = recommended, B = potential, C = not recommended) for each instrument; and (8) reporting of feasibility, interpretability, and any conflicts of interest or developer involvement. In RWE terms, the analogues of design transparency and fitness-for-use are the construct-to-population mapping and the content-validity chain; phenotype/algorithm validation maps onto measurement-property validation; and the "estimand" question becomes whether the instrument actually measures the intended construct in the intended use context.
When NOT to use — limitations and common misapplications
— PRISMA-COSMIN is a reporting checklist, not a risk-of-bias instrument and not a quality score; completing all 54 sub-items documents transparency but does not establish that any instrument is valid — that judgment comes from the COSMIN methodology and Risk of Bias checklist. The single most common misapplication is conflating the three COSMIN artifacts: PRISMA-COSMIN (what to report), the COSMIN methodology / Prinsen 2018 (how to conduct and synthesize the review), and the COSMIN Risk of Bias checklist / Mokkink 2017 (how to appraise each primary study). Other failure modes: using base PRISMA 2020 for an OMI review (it has no fields for measurement properties, content validity, or per-instrument recommendations); using PRISMA-COSMIN to report a review of treatment effects that happen to use a PRO endpoint (that is a PRISMA 2020 review); applying it to a single primary validation study (use the COSMIN study-design checklist); and checklist-as-theater — pasting page numbers against items without the underlying content-validity and evidence-grading work actually being done. It also does not adjudicate which instrument to adopt; it governs the reporting of the evidence that informs that choice.
How it maps to this catalog
— The implementing concepts in this repository are the measurement/validation family, not the causal-design family. Instrument selection and the construct it measures connect to pro-rwe (using PROs as endpoints in real-world data) and pro-development (how an OMI is built). The measurement-property evidence that PRISMA-COSMIN requires you to report is generated and appraised in pro-validation, with the broader validation logic shared by algorithm-validation and surrogate-endpoint-validation-rwe. The eligibility-and-extraction discipline parallels study-protocol-or-sap-elements. Reading guide: report the construct/population frame via pro-rwe and pro-development; report the measurement-property and content-validity evidence via pro-validation; situate instrument validity within the same evidentiary stance as algorithm-validation and surrogate-endpoint-validation-rwe.
Applied note (claims/EHR/registry RWE)
When a real-world study needs a PRO endpoint — e.g., selecting PROMIS, EQ-5D, or a disease-specific PROM to be collected in a registry or linked to claims/EHR — a PRISMA-COSMIN–compliant systematic review is the defensible mechanism for choosing a fit-for-purpose instrument before the protocol locks the endpoint. It documents that the chosen OMI has adequate content validity and measurement properties in the actual target population (e.g., older, multimorbid Medicare enrollees, not a clinical-trial sample), which is exactly the fitness-for-use argument an HTA body or regulator will probe when a PRO drives the value or label claim.